Pain Med by Frenk, Steven M. et al.
Factors Associated with Prescription Opioid Analgesic Use in 
the US Population, 2011–2014
Steven M. Frenk, PhD, Susan L. Lukacs, DO, MSPH, Qiuping Gu, MD, PhD
Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, 
Maryland, USA
Abstract
Objective.—This study examined factors associated with prescription opioid analgesic use in the 
US population using data from a nationally representative sample. It focused on factors previously 
shown to be associated with opioid use disorder or overdose. Variations in the use of different 
strength opioid analgesics by demographic subgroup were also examined.
Methods.—Data came from respondents aged 16 years and older who participated in the 
National Health and Nutrition Examination Survey (2011–2014). Respondents were classified as 
opioid users if they reported using one or more prescription opioid analgesics in the past 30 days.
Results.—Opioid users reported poorer self-perceived health than those not currently using 
opioids. Compared with those not using opioids, opioid users were more likely to rate their health 
as being “fair” or “poor” (40.4% [95% confidence interval {CI} = 34.9%–46.2%] compared with 
15.6% [95% CI = 14.3%–17.1%]), experienced more days of pain during the past 30 days (mean = 
14.3 [95% CI = 12.9–15.8] days compared with 2.3 [95% CI = 2.0–2.7] days), and had depression 
(22.5% [95% CI = 17.3%–28.7%] compared with 7.1% [95% CI = 6.2%–8.0%]). Among those 
who reported using opioids during the past 30 days, 18.8% (95% CI = 14.4%–24.1%) reported 
using benzodiazepine medication during the same period and 5.2% (95% CI = 3.5%–7.7%) 
reported using an illicit drug during the past six months. When opioid strength was examined, a 
smaller percentage of adults aged 60 years and older used stronger-than-morphine opioids 
compared with adults aged 20–39 and 40–59 years.
Conclusions.—Higher percentages of current opioid users than nonusers reported having many 
of the factors associated with opioid use disorder and overdose.
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Introduction
The use of prescription opioid analgesics has increased during the past two decades [1–3]. 
As of 2011–2012, 6.9% of adults aged 20 years and older reported using a prescription 
opioid analgesic in the past 30 days [4]. This increase in opioid use has corresponded with 
increases in the rates of opioid use disorder and opioid-related deaths [5–7]. Significant 
resources have been mobilized to develop prescription guidelines to decrease these adverse 
outcomes [8–10].
As part of the effort to reduce opioid-related adverse outcomes, researchers have examined 
the characteristics of opioid users to understand factors associated with opioid use disorder 
and overdose. These associated factors include poor mental health, illicit drug use, alcohol 
abuse, and concurrent use of benzodiazepine and antidepressant medications [11–15]. In 
addition, variation in opioid analgesic strength is also a concern due to greater risk of opioid 
use disorder from using stronger-than-morphine opioids [8]. Most of this research, however, 
has focused on opioid users within specific cohorts or subgroups, for example, Medicaid 
users, opioid users within a specific geographic location, or people who report having 
chronic pain [13,16,17].
The study’s objective was to examine factors associated with the use of prescription opioid 
analgesics using the most current data available from a nationally representative sample of 
the noninstitutionalized US population. It focused on factors shown in prior research to be 
associated with opioid use disorder or overdose. Variations in the use of different strength 
opioid analgesics by demographic subgroups were also examined.
Methods
Data
The National Health and Nutrition Examination Survey (NHANES) is a continuous, cross-
sectional survey conducted by the National Center for Health Statistics (NCHS). A complex, 
multistage probability sampling design is used to generate a representative sample of the 
civilian, noninstitutionalized US population [18,19]. Participants receive a detailed in-home 
interview followed by a physical examination at a mobile examination center (MEC). As 
part of the MEC exam, participants are asked to complete a health interview including 
questions on alcohol and drug use, pain experiences, and depression in a private setting. 
Study protocols were approved by the NCHS Research Ethics Review Board, and informed 
consent was obtained from all participants. Data are collected continuously but are released 
in two-year cycles. Data from two cycles of two years were included in the analysis: 2011–
2012 and 2013–2014. The examination response rates for each cycle were 69.5% and 
68.5%, respectively [20]. The analytic sample included all NHANES respondents aged 16 
years and over who completed the household interview and physical examination and had no 
missing data on questions regarding their use of prescription medication (N = 12,114).
Variables
Prescription Opioid Use and Strength—Data on prescription medications used in the 
past 30 days were collected during the household interview. Respondents aged 16 years and 
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older were asked: “In the past 30 days, have you used or taken medication for which a 
prescription is needed?” Those who answered affirmatively were asked to show their 
prescription medication containers to the interviewer and report details related to their use. 
The interviewer examined the containers and recorded the exact product names from their 
labels. If containers were not available, the participant verbally reported this information. In 
2013–2014, interviewers could indicate that they had recorded the medication’s name from 
the documentation (printout) respondents received from the pharmacy when they filled their 
prescription (if the medication’s container was not available). In 2011–2014, 85.8% of the 
drug product names were recorded by direct observation of the container, 2.9% were 
recorded based on the pharmacy printout, and the rest (11.3%) were collected via 
respondents’ recall. Except for the minor change noted above, the collection methodology 
was similar for both NHANES cycles [21]. NCHS classified the prescription medications 
based on the therapeutic classification scheme of Cerner Multum’s Lexicon Plus propriety 
database [22].
Two Multum ingredient categories (narcotic analgesics and narcotic analgesic combinations) 
were used to identify opioid analgesic medications, similar to prior research [4]. Opioids that 
were identified were then categorized based on their strength relative to morphine using a 
classification scheme used in prior research [4,23]: weaker than morphine (codeine, 
dihydrocodeine, meperidine, pentazocine, propoxyphene, and tramadol), morphine 
equivalent (hydrocodone, morphine, and tapentadol), or stronger than morphine (fentanyl, 
hydromorphone, methadone, oxycodone, and oxymorphone). Respondents who reported 
using two or more opioid analgesics in the past 30 days (about 12% of opioid users) were 
categorized based on the strongest opioid they reported.
Other Prescription Medication Variables—Three additional variables were derived 
from the prescription medication data. Two were binary variables: One indicated whether 
respondents used prescription benzodiazepines during the past 30 days (Multum categories 
benzodiazepine anticonvulsants and benzodiaze-pines), and the other indicated whether 
respondents used prescription antidepressants during the past 30 days (Multum category 
antidepressants). The third was a variable assessing total number of nonopioid prescription 
medications used in the past 30 days (0, 1–3, 4–6, 7+).
Demographic Variables—Demographic variables included respondents’ age (16–19, 20–
39, 40–59, 60+ years), sex (male, female), race/Hispanic origin (non-Hispanic white, non-
Hispanic black, non-Hispanic Asian, Hispanic), and health insurance status (have health 
insurance, do not have health insurance).
Health Measures—Factors associated with opioid use included a dichotomous measure of 
self-rated health (excellent/very good/good, fair/poor) [24]; the number of days (out of 30) 
pain made it difficult to complete usual activities (0, 1–13, 14–29, 30 days); the number of 
days (out of 30) respondents felt worried, tense, or anxious (0, 1–13, 14–29, 30 days); and 
whether respondents had depression during the past two weeks, indicated by having a score 
of 10 or higher on the Patient Health Questionnaire (PHQ-9), a depression screening 
instrument [25]. These variables come from an interview conducted during the MEC 
examination.
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Health Risk Behaviors—Two health risk behaviors were included. A measure of current 
alcohol consumption was included: nondrinker (0 drinks in past year, former drinkers, and 
lifetime abstainers), light drinker (average of 3 or fewer drinks per week), moderate drinker 
(average of 4–14 drinks per week for men; average of 4–7 drinks per week for women), and 
heavy drinker (average of 15 or more drinks per week for men; average of 8 or more drinks 
per week for women) [26]. A dichotomous variable (yes/no) indicating whether respondents 
used one or more of the following illicit drugs (cocaine, heroin, methamphetamine, and 
other injected drugs not prescribed by a doctor) during the past six months was also created. 
Like the health measures, information on these behaviors came from an interview conducted 
during the MEC examination.
Data Analysis
The analysis was conducted in three parts. First, estimates of demographics, health 
measures, and high-risk behaviors among those who used prescription opioids during the 
past 30 days were generated and then compared with estimates from those who did not use 
opioids during the past 30 days. Differences in the mean number of days experiencing pain, 
the mean number of days experiencing anxiety, and the mean number of nonopioid 
prescriptions were also compared. Adjusted Wald tests were used to test for significant 
differences in characteristics between opioid users and nonusers in the first part of the 
analysis.
Next, odds ratios of using a prescription opioid in the past 30 days were calculated by 
associated covariates identified in the first part of the study. Two types of logistic regression 
models were used: an unadjusted model and a model with adjustment for demographic 
characteristics (age, sex, race/Hispanic origin) and health insurance status to account for 
physiological differences, social context, and access to medical services [27].
Finally, variations in the strength of opioids used by age, sex, and race/Hispanic origin were 
assessed using chi-square tests. If significant differences were found, adjusted Wald tests 
were run to test for differences among age, sex, and race/Hispanic origin groups. For all tests 
performed, a significance level of 0.05 was utilized.
Statistical analyses were conducted applying the complex sampling parameters using the 
SVY commands in Stata 15 to adjust for differential probabilities of selection and the 
complex sampling design [28]. Exam sample weights were used to obtain estimates 
representative of the civilian, noninstitutionalized US population aged 16 years and older. 
Variance estimates were computed using the Taylor series linearization approximation 
method.
Results
Characteristics of Opioid Users
Table 1 presents the prevalence of factors associated with opioid use for current opioid 
analgesic users and those not currently using opioids. In 2011–2014, 6.7% (95% CI = 5.8–
7.8) of respondents aged 16 years and older reported using at least one prescription opioid 
analgesic in the past 30 days.
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Across the demographic variables examined, significant differences between adult opioid 
users and adults who had not used opioids in the past 30 days were identified. The mean age 
of opioid users (mean = 51.8 [95% CI = 49.8–53.7] years) was higher than the mean age of 
adults not using opioids (mean = 44.9 [95% CI = 44.0–45.9] years) due to the larger 
proportion of opioid users in the 40–59 and 60+ age groups. Sex differences between current 
opioid users and nonopioid users were also identified (for men, 43.5% [95% CI = 39.0%–
48.2%] vs 48.6% [95% CI = 47.6%–50.0%]; for women 56.5% [95% CI = 51.8%–61.0%] vs 
51.4% [95% CI = 50.4%–52.4%]). Compared with adults not currently using opioids, opioid 
users were more likely to be non-Hispanic white (72.9% [95% CI = 65.8%–79.0%] vs 
64.9% [95% CI = 59.6%–69.8%]) and less likely to be non-Hispanic Asian (1.3% [95% CI = 
0.8%–2.1%] vs 5.5% [95% CI = 4.5%–6.8%) or Hispanic (9.3% [95% CI = 6.2%–13.6%] vs 
15.3% [95% CI = 12.1%–19.2%]).
Compared with those not currently using opioids, opioid users reported worse health 
outcomes across all examined health measures. Compared with those not using opioids, 
opioid users were more likely to report their overall health as “fair” or “poor” (40.4% [95% 
CI = 34.9%–46.2%] vs 15.6% [95% CI = 14.3%–17.1%]), more days of pain (during the 
past 30 days) that made it difficult to complete their usual activities (mean = 14.3 [95% CI = 
12.9–15.8] days vs mean = 2.3 [95% CI = 2.0–2.7] days), experiencing more days of anxiety 
(during the past 30 days) that impacted their usual activities (mean = 9.5 [95% CI = 7.7–
11.2] days vs mean = 5.3 [95% CI = 4.9–5.7] days), and having depression during the past 
two weeks (22.5% [95% CI = 17.3%–28.7%] vs 7.1% [95% CI = 6.2%–8.0%]).
Opioid users reported using a higher number of nonopioid prescription medications in the 
past 30 days than those not currently using opioids. A larger proportion of opioid users used 
benzodiazepines in the past 30 days (18.8% [95% CI = 14.4%–24.1%] vs 3.4% [95% CI = 
2.9%–4.0%]) or used antidepressants in the past 30 days (35.1% [95% CI = 30.6%–39.8%] 
vs 11.8% [95% CI = 10.6%–13.2%]) compared with those not currently using opioids.
Opioid users were more likely to be nondrinkers compared with those not currently taking 
opioids (34.7% [95% CI = 29.1%–40.8%] vs 26.1% [95% CI = 23.2%–29.3%]) and were no 
more likely to be heavy drinkers compared with that group (7.8% [95% CI = 4.9%–12.1%] 
vs 7.5% [95% CI = 6.7%–8.5%]). Despite being more likely to be nondrinkers, 19.9% of 
opioid users reported that they were “moderate” or “heavy” drinkers. Opioid users were 
more likely to have used illicit drugs during the past six months than those not currently 
taking opioids (5.2% [95% CI = 3.5%–7.7%] vs 2.8% [95% CI = 2.2%–3.5%]).
Table 2 presents the odds ratios and adjusted odds ratios between the covariates and using at 
least one opioid analgesic. All covariates were associated with opioid use in the past 30 
days, although non-Hispanic black race and being a heavy alcohol drinker did not reach 
statistical significance. These associations persisted after adjusting for demographic 
variables and health insurance status, except for respondent’s sex, which was no longer 
significant. The largest adjusted odds ratios observed were for experiencing pain on 14–29 
days and 30 days out of the past 30 days (adjusted odds ratio [AOR] = 14.2 [95% CI = 8.3–
24.4]; AOR = 26.6 [95% CI = 17.9–39.5]), using seven or more prescription medications 
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(AOR = 20.8 [95% CI = 13.8–31.5]), and using benzodiazepines concurrently with opioids 
(AOR = 5.6 [95% CI = 4.1–7.7]).
Strength of Opioids by Demographic
Characteristics—Figure 1 presents the estimates of strength of opioid used overall, by 
age group, sex, and race/Hispanic origin. During 2011–2014, 22.1% (95% CI = 18.5%–
26.1%) of current opioid users used weaker-than-morphine opioids, 47.1% (95% CI = 
42.7%–51.6%) used morphine equivalent opioids, and 30.8% (95% CI = 26.0%–36.0%) 
used stronger-than-morphine opioids. There was no significant difference in strength of 
opioid use between men and women. A larger percentage of opioid users aged 60 years and 
older used weaker-than-morphine opioids compared with adults aged 20–39 and 40–59 
years (30.4% [95% CI = 23.2%–38.7%] vs 14.4% [95% CI = 8.4%–23.7%] and 19.5% 
[15.3%–24.6%], respectively). Conversely, a smaller percentage of opioid users aged 60 
years and older used stronger-than-morphine opioids compared with adults aged 20–39 and 
40–59 years (21.1% [95% CI = 16.0%–29.7%] vs 37.9% [95% CI = 26.4%–51.0%] and 
33.8% [27.5%–40.9%], respectively). A larger percentage of non-Hispanic white opioid 
users used a stronger-than-morphine opioid compared with non-Hispanic black and Hispanic 
opioid users (34.9% [95% CI = 29.8%–40.3%] vs 18.9% [95% CI = 13.5%–25.6%] and 
21.6% [95% CI = 12.8%–34.0%], respectively). A larger percentage of Hispanic users used 
morphine equivalent opioids than non-Hispanic white and non-Hispanic black users (61.3% 
[95% CI = 46.4%–74.4%] vs 45.2% [95% CI = 40.0%–50.4%] and 46.2% [95% CI = 
40.0%–52.6%]). A larger percentage of non-Hispanic black opioid users used weaker-than-
morphine opioids compared with non-Hispanic white and Hispanic opioid users (34.9% 
[95% CI = 29.3%–40.9%] vs 20.0% [95% CI = 15.8%–24.8%] and 17.1% [95% CI = 
10.0%–27.7%]).
Discussion
The Centers for Disease Control and Prevention Guideline for Prescribing Opioids for 
Chronic Pain [8], published in 2016, addressed several factors associated with opioid use 
disorder and overdose. These factors included poor mental health, alcohol consumption, 
illicit drug use, and concurrent use of opioids and benzodiaze-pines [8–10,14,29]. This study 
examined the prevalence of these factors in a recent nationally representative sample of the 
noninstitutionalized US population. Using prior research as a guide, it examined these 
factors among those aged 16 years and older using a wide array of self-reported health and 
health risk behavior measures [3,12,17]. In many instances, these factors were more 
prevalent among current opioid users than among those not currently using opioids. Larger 
percentages of opioid users reported poorer health including mental health problems (i.e., 
frequent anxiety and depression), concurrent use of benzodiazepines and antidepressants, 
and illicit drug use. Although opioid users were less likely to report moderate alcohol 
consumption and as likely to report heavy drinking as nonopioid users, approximately 20% 
of opioid users reported currently being moderate or heavy drinkers, which is not 
recommended when taking opioids [9].
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Current opioid users reported experiencing more frequent pain that made it difficult to 
complete usual activities than those not currently taking opioids. In the adjusted regression 
analysis, the adjusted odds ratios for pain were some of the largest observed in this study. As 
opioid analgesics are used to reduce pain, this association may not be unexpected. However, 
approximately one-quarter of current opioid users reported experiencing zero days of pain 
that limited current activities. The findings presented here could be due to the effectiveness 
of opioids and their ability to relieve pain to the point where it no longer limits users’ 
activities. However, it is not possible to confirm this because the data come from a cross-
sectional survey and data on opioid use and some of the factors examined were collected at 
different times (i.e., during the household exam and the physical exam at the MEC). These 
findings might indicate adverse selection, a phenomenon in which high-risk patients, 
including those with more severe and treatment-resistant pain conditions, tend to be 
prescribed high-risk opioid regimes rather than nonopioid medications, such as nonsteroidal 
anti-inflammatory drugs [30–32].
The examination of opioid strength by demographic characteristics expands the 
understanding of the variation in strength-of-opioid use. As shown in prior research, 
morphine equivalent opioids were the most frequently used, followed by stronger-than-
morphine opioids, and then weaker-than-morphine opioids [4]. Although women were more 
likely to be using opioids than men in this study, the strength of the opioids used did not 
differ. Opioid users aged 60 years and older were more likely to use weaker-than-morphine 
opioids and less likely to use stronger-than-morphine opioids than opioid users aged 20–39 
and 40–59 years. This finding is in line with general clinical guidelines to avoid giving high-
strength opioids to elderly adults due to their greater pharmacodynamic sensitivity to them 
[33]. The findings also identified differences in strength of opioid use among race/Hispanic 
origin groups. Compared with non-Hispanic white opioid users, a larger percentage of non-
Hispanic black opioid users used a weaker-than-morphine opioid. In contrast, a larger 
percentage of non-Hispanic white opioid users used stronger-than-morphine opioids than 
non-Hispanic black and Hispanic opioid users.
Limitations
The NHANES is a cross-sectional survey, so it is not possible to determine the causal link 
between current opioid use and the factors examined. The survey does not collect 
medication dosage of reported medications or discern how often the medication was taken 
during the past 30 days. Thus, it was not possible to calculate the total daily dosage of 
opioids (morphine milligram equivalent per day [MME/d]), which would provide a more 
nuanced assessment of opioid use and could avoid potentially misclassifying opioid strength 
based on the classification system used for this analysis. Finally, NHANES does not have 
data on misuse of opioids.
Strengths
Data for this analysis come from a nationally representative sample of the US 
noninstitutionalized population, which allowed for the generation of estimates that were 
representative of the US noninstitutionalized population aged 16 years and older. 
Prescription medication data were primarily collected by direct observation of medicine 
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containers and categorized based on procedures used in prior pharmacoepidemiological 
studies on opioid analgesic use [4]. A wide of array of self-reported health measures and 
measures of health risk behaviors were incorporated into the analysis. Finally, the study 
examined variations in the strength of opioids across several demographic subgroups.
Conclusion
Current opioid users in the United States reported poor health status and engaging in health 
risk behaviors that have been shown in prior research to be associated with opioid use 
disorder or overdose. These behaviors included illicit drug use and concurrent use of 
benzodiazepines. The use of different strengths of opioids may vary by age and race/
Hispanic origin. These findings may inform other research to further the understanding of 
opioid use in the US population.
Acknowledgment
The authors would like to thank Dr. Brian Kit, MD, MPH, for his assistance with conceptualizing the project and 
revising the manuscript.
Funding sources: None.
References
1. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of 
opioid analgesics from 2004 to 2011. Pain Physician 2014;17(2):E119–28. [PubMed: 24658483] 
2. CDC. Vital signs: Overdoses of prescription opioid pain relievers—United States, 1999–2008. 
MMWR Morb Mortal Wkly Rep 2011;60:1487–92. [PubMed: 22048730] 
3. Mojtabai R National trends in long-term use of prescription opioids. Pharmacoepidemiol Drug Saf 
2018;27(5):526–34. [PubMed: 28879660] 
4. Frenk SM, Porter KS, Paulozzi LJ. Prescription Opioid Analgesic Use Among Adults: United 
States, 1999–2012 NCHS Data Brief, No 189. Hyattsville, MD: National Center for Health 
Statistics; 2015.
5. Dart RC, Surratt HL, Cicero TJ. Trends in opioid analgesic abuse and mortality in the United States. 
N Engl J Med 2015;372(3):241–8. [PubMed: 25587948] 
6. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United 
States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016;65:1445–52. [PubMed: 28033313] 
7. Warner M, Hedegaard H, Chen LH. Trends in drug-poisoning deaths involving opioid analgesics 
and heroin: United States, 1999–2012. NCHS health e-stats. 2014 Available at: http://www.cdc.gov/
nchs/data/hestat/drug_poisoning/drug_poisoning_deaths_1999-2012.pdf (accessed December 
2016).
8. Dowell D, Haegerich TM, Chou R. CDC guidelines for prescribing opioids for chronic pain—
United States, 2016. JAMA 2016;315(15):1624–45. [PubMed: 26977696] 
9. US Food and Drug Administration. 2016 FDA warns about serious risk and death when combining 
opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Drug Safety 
Communications. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf 
(accessed December 2016).
10. Weiner SG, Raja AS, Bittner JC, et al. Opioid-related policies in New England emergency 
departments. Acad Emerg Med 2016;23(9):1086–90. [PubMed: 27098615] 
11. Jann M, Kennedy WK, Lopez G. Benzodiazepines: A major component in unintentional 
prescription drug overdoses with opioid analgesics. J Pharm Pract 2014;27(1):5–16. [PubMed: 
24436437] 
Frenk et al. Page 8
Pain Med. Author manuscript; available in PMC 2020 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
12. Larochelle MR, Zhang F, Ross-Degnan D, et al. Trends in opioid prescribing and co-prescribing of 
sedative hypnotics for acute and chronic musculoskeletal pain: 2001–2010. Pharmacoepidemiol 
Drug Saf 2015;24(8):885–92. [PubMed: 25906971] 
13. Mack KA, Zhang K, Paulozzi L, et al. Prescription practices involving opioid analgesics among 
Americans with Medicaid, 2010. J Health Care Poor Underserved 2015;26(1):182–98. [PubMed: 
25702736] 
14. Paulozzi LJ. Prescription drug overdoses: A review. J Safety Res 2012;43(4):283–9. [PubMed: 
23127678] 
15. West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. 
Pharmacoepidemiol Drug Saf 2016;25(5):539–44. [PubMed: 26660909] 
16. Baumblatt JAG, Wiedeman C, Dunn J, et al. High-risk use by patients prescribed opioids for pain 
and its role in overdose deaths. JAMA Intern Med 2014;174(5):796–801. [PubMed: 24589873] 
17. Edlund MJ, Martin BC, Fan M- Y, et al. Risk for opioid abuse and dependence among recipients of 
chronic opioid therapy: Results from the TROUP study. Drug Alcohol Depend 2010;112(1–2):90–
8. [PubMed: 20634006] 
18. Zipf G, Chiappa M, Porter KS, et al. National health and nutrition examination survey: Plan and 
operations, 1999–2010. National Center for Health Statistics. Vital Health Stat 2013;1:1–37.
19. National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of 
Health and Human Services, Centers for Disease Control and Prevention; 2011 Available at: http://
www.cdc.gov/nchs/nhanes/about_nhanes.htm (accessed December 2016).
20. Division of Health and Nutrition Examination Surveys. NHANES response rates and population 
totals. 2015 Available at: https://wwwn.cdc.gov/nchs/nhanes/ResponseRates.aspx (accessed 
December 2016).
21. National Center for Health Statistics. 2011 Dietary supplements and prescription medication—
DSQ. Available at: https://wwwn.cdc.gov/nchs/data/nhanes/2011-2012/questionnaires/dsq.pdf 
(accessed December 2016).
22. NCHS. National Health and Nutrition Examination Survey, 1988–2014 data documentation, 
codebook, and frequencies: Prescription medications—drug information. 2016 Available at: 
https://wwwn.cdc.gov/Nchs/Nhanes/1999-2000/RXQ_DRUG.htm (accessed December 2016).
23. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer 
pain. Clin J Pain 2008;24(6):521–7. [PubMed: 18574361] 
24. Manor O, Matthews S, Power C. Dichotomous or categorical response? Analysing self-rated health 
and lifetime social class. Int J Epidemiol 2000;29(1):149–57. [PubMed: 10750617] 
25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J 
Gen Intern Med 2001;16(9):606–13. [PubMed: 11556941] 
26. Fryar CD, Hirsch R, Porter KS, et al. Smoking and Alcohol Behaviors Reported by Adults, United 
States 1999–2002 Advance Data from Vital and Health Statistics; No 378. Hyattsville, MD: 
National Center for Health Statistics; 2006.
27. Zedler B, Xie L, Wang L, Joyce A, et al. Risk factors for serious prescription opioid-related 
toxicity or overdose among Veterans Health Administration Patients. Pain Med 2014;15(11):1911–
29. [PubMed: 24931395] 
28. StataCorp. Stata Statistical Software: Release 15 [computer program]. College Station, TX: 
StataCorp LLC; 2017.
29. Webster LR, Dasgupta N. An analysis of the root cause for opioid-related overdose deaths in the 
United States. Pain Med 2011;12(suppl 2):S26–35. [PubMed: 21668754] 
30. Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the United States: Promises and perils. 
Pain 2013;154:S94–100. [PubMed: 24036286] 
31. Campbell G, Nielsen S, Larance B, et al. Pharmaceutical opioid use and dependence among people 
living with chronic pain: Associations observed within the pain and opioids in treatment (POINT) 
cohort. Pain Med 2015;16(9):1745–58. [PubMed: 26011277] 
32. Henry SG, Wilsey BL, Melnikow J, Iosif AM. Dose elscalation during the first year of long-term 
opioid therapy for chronic pain. Pain Med 2015;16(4):733–44. [PubMed: 25529548] 
33. Naples JG, Gellad WF, Hanlon JT. Managing pain in older adults: The role of opioid analgesics. 
Clin Geriatr Med 2016;32(4):725–35. [PubMed: 27741966] 
Frenk et al. Page 9
Pain Med. Author manuscript; available in PMC 2020 January 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Strength of opioid analgesic among opioid users aged 16 years and older by demographic 
characteristics, NHANES 2011–2014.
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am
 sa
m
pl
e 
w
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gh
ts 
w
er
e 
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ze
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dju
st 
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ffe
re
nt
ia
l p
ro
ba
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lit
ie
s o
f s
el
ec
tio
n 
an
d 
th
e 
co
m
pl
ex
 s
am
pl
in
g 
de
sig
n.
 P
er
ce
nt
ag
es
 d
o 
no
t s
um
 to
 1
00
 d
ue
 to
 ro
un
di
ng
. R
es
po
nd
en
ts 
w
er
e 
as
ke
d,
 “
In
 th
e 
pa
st 
30
 d
ay
s, 
ha
v
e 
yo
u 
us
ed
 o
r t
ak
en
 m
ed
ic
at
io
n 
fo
r w
hi
ch
 a
 p
re
sc
rip
tio
n 
is 
ne
ed
ed
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 A
dju
ste
d m
od
els
 in
clu
de
 re
spo
nd
en
ts’
 ag
e (
co
nti
nu
ou
s),
 se
x
 (d
ich
oto
mo
us
), r
ac
e/H
isp
an
ic 
ori
gin
 (c
ate
go
ric
al
), a
nd
 
he
al
th
 in
su
ra
nc
e 
sta
tu
s (
dic
ho
tom
ou
s).
CI
 =
 c
on
fid
en
ce
 in
te
rv
al
; O
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od
ds
 ra
tio
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tim
at
es
 fo
r p
er
so
ns
 o
f o
th
er
 ra
ce
/H
isp
an
ic
 o
rig
in
 g
ro
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s a
re
 n
ot
 p
ro
v
id
ed
 se
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ra
te
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bu
t m
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 o
f t
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s g
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sti
m
at
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t p
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at
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in
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 d
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s);
 lig
ht 
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er
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v
er
ag
e 
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r f
ew
er
 d
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er
 w
ee
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te 
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nk
er
 (a
v
er
ag
e 
of
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–1
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in
ks
 p
er
 w
ee
k 
fo
r m
en
; a
v
er
ag
e 
of
 4
–
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dr
in
ks
 p
er
 w
ee
k 
fo
r w
o
m
en
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he
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y 
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in
ke
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(av
er
ag
e 
of
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5 
or
 m
or
e d
rin
ks
 p
er
 w
ee
k 
fo
r m
en
; a
v
er
ag
e 
of
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 o
r m
or
e 
dr
in
ks
 p
er
 w
ee
k 
fo
r w
o
m
en
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he
se 
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est
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ere
 on
ly 
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ed
 o
f r
es
po
nd
en
ts 
ag
ed
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8 
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ar
s a
nd
 o
ld
er
.
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g 
co
ca
in
e,
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 m
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/o
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th
er
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e p
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f r
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po
nd
en
ts 
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ed
 1
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